| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| InCube Labs, L.L.C. | 22% | $13,541,357 | 27,093,552 | MIR A IMRAN | 23 Oct 2025 | |||
| Samsara BioCapital, L.P. | 9.9% | $4,939,262 | 9,882,477 | Srinivas Akkaraju | 23 Oct 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $4,939,262 | 9,882,477 | RA Capital Management, L.P. | 23 Oct 2025 | |||
| Invus Global Management, LLC | 10% | $4,910,990 | 9,825,911 | Raymond Debbane | 16 Oct 2025 | |||
| ARMISTICE CAPITAL, LLC | 9.9% | $4,131,600 | 6,260,000 | Armistice Capital, LLC | 30 Jun 2025 | |||
| South Cone Investments Limited Partnership | 4.9% | $1,189,121 | 2,379,194 | South Cone Investments Limited Partnership | 20 Oct 2025 | |||
| Orca Capital AG | 4.3% | -56% | $972,105 | -$1,265,416 | 1,891,623 | -57% | Orca Capital AG | 22 Jul 2025 |
As of 30 Sep 2025, 36 institutional investors reported holding 4,033,213 shares of Rani Therapeutics Holdings, Inc. - Class A Common Stock, $0.0001 par value per share (RANI). This represents 4% of the company’s total 99,823,000 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 218,076 | $294,403 | +$1,696 | $1.35 | 3 |
| 2025 Q3 | 4,033,213 | $2,015,817 | -$1,258,453 | $0.50 | 36 |
| 2025 Q2 | 6,458,632 | $3,319,783 | +$1,060,111 | $0.51 | 38 |
| 2025 Q1 | 3,609,389 | $4,577,211 | -$332,797 | $1.26 | 38 |
| 2024 Q4 | 3,819,967 | $5,233,595 | -$4,950,047 | $1.37 | 42 |
| 2024 Q3 | 5,911,071 | $12,767,865 | +$5,999,502 | $2.16 | 31 |
| 2024 Q2 | 3,108,475 | $11,809,884 | -$1,252,441 | $3.80 | 33 |
| 2024 Q1 | 3,453,784 | $10,741,251 | +$509,498 | $3.11 | 35 |
| 2023 Q4 | 3,290,303 | $10,923,496 | -$819,783 | $3.32 | 33 |
| 2023 Q3 | 3,207,291 | $6,961,738 | -$151,646 | $2.18 | 32 |
| 2023 Q2 | 3,227,286 | $13,256,941 | +$994,179 | $4.12 | 34 |
| 2023 Q1 | 2,999,366 | $15,475,095 | +$204,634 | $5.16 | 35 |
| 2022 Q4 | 2,885,407 | $17,024,416 | -$1,472,942 | $5.90 | 32 |
| 2022 Q3 | 3,174,344 | $30,405,447 | +$3,581,808 | $9.58 | 30 |
| 2022 Q2 | 2,824,819 | $29,094,000 | +$2,769,956 | $10.33 | 27 |
| 2022 Q1 | 2,556,816 | $34,515,000 | +$17,568,047 | $13.50 | 23 |
| 2021 Q4 | 1,240,919 | $20,288,000 | +$544,189 | $16.35 | 21 |
| 2021 Q3 | 1,097,698 | $19,562,000 | +$19,562,000 | $17.82 | 14 |